Tirzepatide Injection
A once-weekly dual-action GIP/GLP-1 receptor agonist that targets two hormonal pathways involved in appetite regulation and metabolic function. Prescribed by licensed providers.
No commitment required. Free assessment takes ~5 minutes.
How Tirzepatide Works
Tirzepatide is a first-in-class dual-action molecule that activates both GIP and GLP-1 receptors, two key pathways involved in metabolism and appetite control.
GLP-1 Pathway
Activates GLP-1 receptors to help regulate appetite signaling and blood sugar response, similar to semaglutide.
GIP Pathway
Additionally activates GIP receptors, which play a role in fat metabolism and energy balance, a pathway unique to tirzepatide.
Dual-Action Benefit
The combination of both pathways may offer a complementary approach to appetite regulation and metabolic support.
Typical Dosage Schedule
Your healthcare provider determines the appropriate dosing for your individual needs. The schedule below is a general guideline.
Starting dose to assess tolerance. Most patients experience minimal initial side effects.
First dose increase. Your provider evaluates your response before continuing escalation.
Gradual escalation toward therapeutic range.
Continued titration. Most patients notice meaningful changes during this phase.
Full therapeutic dose range. Your provider adjusts based on your individual response and tolerance.
Potential Side Effects
Like all medications, tirzepatide may cause side effects. Most are mild and improve over time. Discuss risks and benefits with your provider.
Nausea
CommonUsually mild and temporary. Most common during dose escalation periods.
Diarrhea
CommonTypically resolves as your body adjusts to the medication.
Decreased appetite
CommonA known effect of the medication's mechanism of action.
Constipation
Less commonSome patients experience changes in bowel habits.
Injection site reactions
Less commonMinor redness or discomfort at the injection site.
This is not a complete list of side effects. Serious side effects are rare but possible. Contact your healthcare provider or seek emergency care for severe symptoms.
Clinical Evidence
Published clinical trial data for FDA-approved tirzepatide (Mounjaro/Zepbound). Compounded tirzepatide has not been independently evaluated in clinical trials.
~21%
Average body weight reduction
In the SURMOUNT-1 trial, participants receiving the highest dose (15 mg) lost an average of ~21% of body weight over 72 weeks vs. ~3.1% with placebo.
Jastreboff et al., NEJM 2022
2,539
Participants in SURMOUNT-1
The SURMOUNT-1 trial enrolled 2,539 adults with BMI ≥30 (or ≥27 with comorbidity), demonstrating significant weight reduction across all dose groups.
SURMOUNT-1 Trial, NCT04184622
91%
Achieved ≥5% weight loss
At the 15 mg dose, 91% of participants achieved at least 5% weight loss compared to 35% in the placebo group.
Jastreboff et al., NEJM 2022
These results are from clinical trials of FDA-approved tirzepatide (Mounjaro/Zepbound), not compounded tirzepatide. Compounded medications are not FDA-approved and have not been evaluated in equivalent clinical trials. Individual results may vary. All participants also received lifestyle counseling.
What to Expect
A general guide based on published clinical data for FDA-approved tirzepatide. Your experience may differ.
Adjustment Period
Starting dose helps your body adapt to the dual GIP/GLP-1 mechanism. Most patients notice reduced appetite early. Mild GI side effects are common but typically resolve.
Early Progress
As doses escalate, the dual-action mechanism becomes more pronounced. In clinical trials, meaningful weight changes typically began during this period.
Sustained Results
Patients approaching maintenance dose often report stabilized appetite, improved metabolic markers, and continued progress. Provider monitors and adjusts as needed.
Long-Term Management
Ongoing treatment supports sustained progress. The dual-action mechanism continues to work on both GIP and GLP-1 pathways. Regular provider check-ins ensure optimal care.
Results may vary. This timeline is illustrative and based on published data for FDA-approved tirzepatide. No specific outcome is guaranteed with compounded medications.
Simple, Transparent Pricing
Provider consultation, medication, and shipping included. Cancel anytime.
$269/mo
- Licensed clinician consultation
- Compounded tirzepatide injection
- Dual GIP/GLP-1 receptor agonist
- Free priority shipping
- Ongoing provider support
- Monthly dose adjustments
- No insurance required
Free assessment. No obligation.
Considering Semaglutide Instead?
Both are effective GLP-1 receptor agonists. Your healthcare provider will help determine which is right for you.
View Semaglutide Details →Frequently Asked Questions
What is compounded tirzepatide?
How is tirzepatide different from semaglutide?
Who is eligible for tirzepatide?
How long before I see results?
Can I switch from semaglutide to tirzepatide?
What if tirzepatide is not right for me?
Ready to Get Started?
Take our free 5-minute assessment to see if you may qualify for tirzepatide treatment.
Check Your EligibilityCompounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. It is not the same as, equivalent to, or a substitute for FDA-approved brand-name products (e.g., Mounjaro, Zepbound). Compounded medications are prescribed on a patient-specific basis by licensed healthcare providers and prepared by state-licensed 503A compounding pharmacies.
Individual results may vary and depend on multiple factors including starting weight, medication adherence, diet, exercise, and individual health profile. No specific outcome is guaranteed. This page does not constitute medical advice. Always consult with a qualified healthcare provider.
Blue Oak Services LLC dba Prescriva is a management services organization (MSO). All medical services are provided by independently licensed healthcare providers through our partner provider network.